Percheron Therapeutics
Percheron Therapeutics is an Australian publicly-listed biotechnology company dedicated to developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. Their mission is to bring life-changing medicines to patients in need through innovative therapies, leveraging cutting-edge science and strategic partnerships, notably with Ionis Pharmaceuticals. They focus on therapies such as ATL1102 for Duchenne muscular dystrophy and multiple sclerosis, and ATL1103 for acromegaly, aiming to address high unmet medical needs with transparency and stakeholder value.
Industries
Nr. of Employees
small (1-50)
Percheron Therapeutics
Products
ATL1102 (antisense oligonucleotide targeting VLA4)
An antisense oligonucleotide therapeutic candidate targeting VLA4, being developed for Duchenne muscular dystrophy; subject of an international Phase IIb clinical trial and previously evaluated in Phase IIa. Also investigated for multiple sclerosis and granted orphan/rare pediatric regulatory designations.
ATL1103 (antisense oligonucleotide against growth hormone receptor)
An antisense oligonucleotide therapeutic candidate targeting the growth hormone receptor; completed a Phase II clinical study in acromegaly.
ATL1102 (antisense oligonucleotide targeting VLA4)
An antisense oligonucleotide therapeutic candidate targeting VLA4, being developed for Duchenne muscular dystrophy; subject of an international Phase IIb clinical trial and previously evaluated in Phase IIa. Also investigated for multiple sclerosis and granted orphan/rare pediatric regulatory designations.
ATL1103 (antisense oligonucleotide against growth hormone receptor)
An antisense oligonucleotide therapeutic candidate targeting the growth hormone receptor; completed a Phase II clinical study in acromegaly.
Services
In-licensing and partnership collaboration
Sourcing and managing licensing agreements and development collaborations to access antisense drug assets and development expertise.
Investor communications and reporting
Preparation and publication of investor-facing materials including ASX announcements, financial reports and corporate presentations.
In-licensing and partnership collaboration
Sourcing and managing licensing agreements and development collaborations to access antisense drug assets and development expertise.
Investor communications and reporting
Preparation and publication of investor-facing materials including ASX announcements, financial reports and corporate presentations.
Expertise Areas
- Antisense therapeutics development
- Clinical trial management for rare diseases
- Regulatory strategy for orphan and rare pediatric designations
- Licensing and partnership development
Key Technologies
- Antisense oligonucleotide therapeutics
- RNA-targeting therapeutics
- Clinical trial design and execution (Phase II)
- Oligonucleotide chemistry and formulation